These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

950 related articles for article (PubMed ID: 17477341)

  • 1. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
    Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL
    ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling promiscuity based on in vitro safety pharmacology profiling data.
    Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
    ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting ADME properties and side effects: the BioPrint approach.
    Krejsa CM; Horvath D; Rogalski SL; Penzotti JE; Mao B; Barbosa F; Migeon JC
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):470-80. PubMed ID: 12951810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early prediction of drug metabolism and toxicity: systems biology approach and modeling.
    Bugrim A; Nikolskaya T; Nikolsky Y
    Drug Discov Today; 2004 Feb; 9(3):127-35. PubMed ID: 14960390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
    Whitebread S; Hamon J; Bojanic D; Urban L
    Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds.
    Prado-Prado FJ; González-Díaz H; de la Vega OM; Ubeira FM; Chou KC
    Bioorg Med Chem; 2008 Jun; 16(11):5871-80. PubMed ID: 18485714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global mapping of pharmacological space.
    Paolini GV; Shapland RH; van Hoorn WP; Mason JS; Hopkins AL
    Nat Biotechnol; 2006 Jul; 24(7):805-15. PubMed ID: 16841068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing better drugs: predicting cytochrome P450 metabolism.
    de Groot MJ
    Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico prediction of harmful effects triggered by drugs and chemicals.
    Vedani A; Dobler M; Lill MA
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):398-407. PubMed ID: 16045954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge of predicting drug toxicity in silico.
    Vedani A; Dobler M; Lill MA
    Basic Clin Pharmacol Toxicol; 2006 Sep; 99(3):195-208. PubMed ID: 16930291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rational approach to maximize success rate in target discovery.
    Schneider M
    Arch Pharm (Weinheim); 2004 Dec; 337(12):625-33. PubMed ID: 15597396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting myelosuppression of drugs from in silico models.
    Crivori P; Pennella G; Magistrelli M; Grossi P; Giusti AM
    J Chem Inf Model; 2011 Feb; 51(2):434-45. PubMed ID: 21275392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging chemical patterns: a new methodology for molecular classification and compound selection.
    Auer J; Bajorath J
    J Chem Inf Model; 2006; 46(6):2502-14. PubMed ID: 17125191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico search of putative adverse drug reaction related proteins as a potential tool for facilitating drug adverse effect prediction.
    Ji ZL; Wang Y; Yu L; Han LY; Zheng CJ; Chen YZ
    Toxicol Lett; 2006 Jul; 164(2):104-12. PubMed ID: 16563668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting antitrichomonal activity: a computational screening using atom-based bilinear indices and experimental proofs.
    Marrero-Ponce Y; Meneses-Marcel A; Castillo-Garit JA; Machado-Tugores Y; Escario JA; Barrio AG; Pereira DM; Nogal-Ruiz JJ; Arán VJ; Martínez-Fernández AR; Torrens F; Rotondo R; Ibarra-Velarde F; Alvarado YJ
    Bioorg Med Chem; 2006 Oct; 14(19):6502-24. PubMed ID: 16875830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of adverse drug reactions using drug and drug target interactions and graph-based methods.
    Lin SF; Xiao KT; Huang YT; Chiu CC; Soo VW
    Artif Intell Med; 2010; 48(2-3):161-6. PubMed ID: 19962282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.